trending Market Intelligence /marketintelligence/en/news-insights/trending/af4q5sewlzszpvntgrpnrw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Xeris Pharmaceuticals closes $98.3M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Xeris Pharmaceuticals closes $98.3M IPO

Xeris Pharmaceuticals Inc. closed its IPO to raise about $98.3 million in gross proceeds.

The Chicago-based specialty pharmaceutical company issued 6,555,000 common shares at $15 apiece. The total includes 859,800 shares bought by the underwriters after they exercised their option in full to buy the additional shares.

The company reported separately June 26 that two late-stage clinical trials showed that its ready-to-use glucagon rescue pen was safe and effective in treating emergency events for type 1 diabetes patients.

Xeris is listed on the Nasdaq Global Select Market under the symbol XERS.

Jefferies, Leerink Partners, RBC Capital Markets and Mizuho Securities acted as joint book running managers for the offering.